WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, August 16, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR		
☐	L10	L9 and succinamid$	8
☐	L9	L8 and stroke$	1314
☐	L8	sulfonamid$ and (caspase$ or interleukin$ or ice or protease)near4(inhibit$ or antagonist$)	3269
☐	L7	L6 and (inhibitor$).ti.	28
☐	L6	L4 and inhibitor$	97
☐	L5	L4 and succinamid$	0
☐	L4	L3 and stroke$	98
☐	L3	l2 and aspart$	208
☐	L2	L1 and (caspase$ or interleukin$ or ice or protease)near4(inhibit$ or antagonist$)	488
☐	L1	(warner)near2(lambert$) or (BASF)near3(aktieng$)	18974

END OF SEARCH HISTORY

09/674,812

(FILE 'HOME' ENTERED AT 14:24:33 ON 16 AUG 2004)

FILE 'STNGUIDE' ENTERED AT 14:24:43 ON 16 AUG 2004

FILE 'HOME' ENTERED AT 14:24:56 ON 16 AUG 2004

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:25:06 ON 16 AUG 2004

L1 3774 S (AUTOLYSIS?)/TI
L2 4 S L1 AND (INTERLEUKIN?)/TI

FILE 'STNGUIDE' ENTERED AT 14:25:49 ON 16 AUG 2004

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:32:14 ON 16 AUG 2004

L3 161 S (CAPRATHE, B? OR CAPRATHE B?)/AU,IN
L4 1565 S (GILMORE, J? OR GILMORE J?)/AU,IN
L5 154 S (HARTER, W? OR HARTER W?)/AU,IN
L6 53 S (GALATSIS, P? OR GALATSIS P?)/AU,IN
L7 134 S (KOSTLAN, C? OR KOSTLAN C?)/AU,IN
L8 1996 S L3 OR L4 OR L5 OR L6 OR L7
L9 54 S (INTERLEUKIN? OR ICE OR CASPASE? OR CYSTEINE? OR PROTEASE?)(3
L10 30 DUP REM L9 (24 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 14:36:59 ON 16 AUG 2004

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:37:25 ON 16 AUG 2004

FILE 'STNGUIDE' ENTERED AT 14:39:28 ON 16 AUG 2004

FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 14:39:49 ON 16 AUG 2004

L11 19 S (HOMO)(2A)(VAL OR VAL)
L12 12 DUP REM L11 (7 DUPLICATES REMOVED)
L13 10 S L10 AND (BENZENESULFON? OR SULFONAMID? OR BENZENESULPHON?)
L14 23233 S (BETA)(3A)(AMINO)(2A)(ACID?)
L15 293 S (INTERLEUKIN? OR ICE OR CASPASE? OR CYSTEINE? OR PROTEASE?)(3
L16 23 S (INTERLEUKIN? OR ICE OR CASPASE?)(3A)(INHIBIT?) AND L15
L17 18 DUP REM L16 (5 DUPLICATES REMOVED)

L10 ANSWER 24 OF 30 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:197761 BIOSIS
DN PREV199799496964
TI Design, synthesis and SAR of benzenesulfonamide derivatives as **inhibitors** of complement C1r **protease** for the treatment of inflammatory processes.
AU Cai, Cuiman; Plummer, Janet S.; Hays, Sheryl J.; **Gilmore, John L.** ; Emmerling, Mark R.; Wang, Kevin; Jaen, Juan C.
CS Parke-Davis Pharmaceutical Res. Div., Warner-Lambert Co., 2800 Plymouth Road, Ann Arbor, MI 48105, USA
SO Abstracts of Papers American Chemical Society, (1997) Vol. 213, No. 1-3, pp. MEDI 87.
Meeting Info.: 213th National Meeting of the American Chemical Society. San Francisco, California, USA. April 13-17, 1997.
CODEN: ACSRAL. ISSN: 0065-7727.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 2 May 1997
Last Updated on STN: 2 Jun 1997

=> d ab

L10 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
AB A series of sulfonamides (1) has been prepared as **inhibitors** of **interleukin**-1β converting enzyme (ICE), also known as caspase 1. These compds. were designed to improve potency by rigidifying the enzyme bound mol. through an intramol. hydrogen bond. An X-ray crystal structure of a representative member of this series bound to the active site of ICE, confirms the presence of the hydrogen bonding interaction.

=> d abs

L10 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
AB A series of sulfonamides (1) has been prepared as **inhibitors** of **interleukin**-1β converting enzyme (ICE), also known as caspase 1. These compds. were designed to improve potency by rigidifying the enzyme bound mol. through an intramol. hydrogen bond. An X-ray crystal structure of a representative member of this series bound to the active site of ICE, confirms the presence of the hydrogen bonding interaction.

L10 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:161919 CAPLUS
ED Entered STN: 10 Mar 1997
TI Design, synthesis and SAR of benzenesulfonamide derivatives as **inhibitors** of complement C1r **protease** for the treatment of inflammatory processes.
AU Cai, Cuiman; Plummer, Janet S.; Hays, Sheryl J.; **Gilmore, John L.** ; Emmerling, Mark R.; Wang, Kevin; Jaen, Juan C.
CS Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
SO Book of Abstracts, 213th ACS National Meeting, San Francisco, April 13-17 (1997), MEDI-087 Publisher: American Chemical Society, Washington, D. C. CODEN: 64AOAA
DT Conference; Meeting Abstract
LA English
AB Serine proteases are a group of endopeptidase enzymes that have a serine amino acid in their active center. C1r in the complement system is serine protease and provides a critical and multifaceted defense system in the host defense against infection. Using 2-substituted 4H-3,1-benzoxazin-4-one and benzthiazin-4-one as our template, and following a topliss tree anal., we synthesized a series of benzenesulfonamide derivs. as potent C1r inhibitors with improved activity. The design, synthesis and structure activity relationship of these improved inhibitors will be presented.

L17 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:868699 CAPLUS
DN 137:370355
TI Preparation of **.beta.-amino acid** arylsulfonamide ether derivatives as **inhibitors** of **interleukin**-1β converting enzyme
IN Knobelsdorf, James; Hays, Sheryl; Stankovic, Charles J.; Para, Kimberly S.; Connolly, Michael K.; Galatsis, Paul; Harter, William; Shahripor, Aurash B.; Plummer, Mark Stephen; Lunney, Beth; Janssen, Bernd; Fell, Jay Bradford
PA Abbott G.m.b.H. & Co. K.-G., Germany; Warner-Lambert Company; et al.
SO PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002089749	A2	20021114	WO 2002-US15002	20020510
	WO 2002089749	A3	20030227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003096826	A1	20030522	US 2002-143675	20020510
	EP 1392280	A2	20040303	EP 2002-734382	20020510
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-289950P	P	20010510		
	WO 2002-US15002	W	20020510		

OS MARPAT 137:370355

09/674,812

(FILE 'HOME' ENTERED AT 15:08:27 ON 16 AUG 2004)

FILE 'REGISTRY' ENTERED AT 15:08:42 ON 16 AUG 2004
L1 STRUCTURE UPLOADED
L2 9581 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:10:01 ON 16 AUG 2004
L3 4711 S L2
L4 13 S L3 AND (SULFONYL? OR SULPHONYL?)

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak,Cb,Cy,Hy
G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=>

L4 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:262147 CAPLUS
DN 130:308784
TI Novel fluorescent reporter molecules and their applications including assays for caspases
IN Weber, Eckard; Cai, Sui Xiong; Keana, John F. W.; Drewe, John A.; Zhang, Han-Zhong
PA Cytovia, Inc., USA
SO PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9918856	A1	19990422	WO 1998-US21231	19981009
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2308125	AA	19990422	CA 1998-2308125	19981009
	AU 9910722	A1	19990503	AU 1999-10722	19981009
	AU 754634	B2	20021121		
	EP 1026988	A1	20000816	EP 1998-953317	19981009
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2001519368	T2	20011023	JP 2000-515498	19981009
	NZ 503619	A	20011130	NZ 1998-503619	19981009
	US 6342611	B1	20020129	US 1998-168888	19981009
	BR 9814816	A	20040622	BR 1998-14816	19981009
	US 6335429	B1	20020101	US 2000-521650	20000308
	US 2002150885	A1	20021017	US 2001-947387	20010907
	US 6759207	B2	20040706		
PRAI	US 1997-61582P	P	19971010		
	US 1998-33661	A	19980303		
	US 1998-145746P	P	19980303		
	US 1998-168888	A3	19981009		
	WO 1998-US21231	W	19981009		

OS MARPAT 130:308784
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:487827 CAPLUS
DN 122:240452
TI Preparation of [[[(amidinophenyl)amino]dioxoalkyl]amino]alkanoates as platelet aggregation inhibitors.
IN Bovy, Philippe R.; Rico, Joseph G.; Rogers, Thomas E.; Tjoeng, Foe S.; Zablocki, Jeffery A.
PA G.D. Searle and Co., USA; Monsanto Co.
SO U.S., 36 pp. Cont.-in-part of U.S. 5,239,113.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5344957	A	19940906	US 1992-953601	19921006
	US 5239113	A	19930824	US 1992-866933	19920410

	AT 150302	E	19970415	AT 1992-921348	19921006
	ES 2099282	T3	19970516	ES 1992-921348	19921006
	EP 542708	A1	19930519	EP 1992-870167	19921014
	EP 542708	B1	20010530		
	R: PT				
	PT 542708	T	20011130	PT 1992-870167	19921014
	US 5625093	A	19970429	US 1995-452621	19950525
	US 5703125	A	19971230	US 1995-455612	19950531
	US 5886208	A	19990323	US 1997-835598	19970410
	US 5973003	A	19991026	US 1997-938856	19970926
PRAI	US 1991-777811	B2	19911015		
	US 1992-866933	A2	19920410		
	US 1992-953601	A3	19921006		
	US 1994-221913	B2	19940401		
	US 1995-452621	A3	19950525		
	US 1995-455612	A1	19950531		
OS	MARPAT 122:240452				

L4 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:539779 CAPLUS
DN 119:139779
TI Preparation of substituted β-amino acid derivatives useful as platelet aggregation inhibitors
IN Bovy, Philippe Roger; Rico, Joseph Gerace; Rogers, Thomas Edward; Tjoeng, Foe Siong; Zablocki, Jeffery Alan
PA Monsanto Co., USA; G.D. Searle and Co.
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9307867	A1	19930429	WO 1992-US8512	19921006
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5239113	A	19930824	US 1992-866933	19920410
	AU 9227608	A1	19930521	AU 1992-27608	19921006
	AU 661724	B2	19950803		
	EP 614360	A1	19940914	EP 1992-921348	19921006
	EP 614360	B1	19970319		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07500111	T2	19950105	JP 1993-507711	19921006
	JP 2813462	B2	19981022		
	AT 150302	E	19970415	AT 1992-921348	19921006
	ES 2099282	T3	19970516	ES 1992-921348	19921006
	CA 2115432	C	20030603	CA 1992-2115432	19921006
	EP 542708	A1	19930519	EP 1992-870167	19921014
	EP 542708	B1	20010530		
	R: PT				
	PT 542708	T	20011130	PT 1992-870167	19921014
PRAI	US 1991-777811	A	19911015		
	US 1992-866933	A	19920410		
	WO 1992-US8512	A	19921006		
OS	MARPAT 119:139779				

L4 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:22602 CAPLUS
DN 118:22602
TI Application of arylsulfonyl side-chain protected arginines in solid-phase peptide synthesis based on 9-fluorenylmethoxycarbonyl amino protecting strategy

AU Fischer, Peter M.; Retson, Kim V.; Tyler, Margaret I.; Howden, Merlin E. H.
CS Deakin Res., North Ryde, Australia
SO International Journal of Peptide & Protein Research (1992), 40(1), 19-24
CODEN: IJPPC3; ISSN: 0367-8377
DT Journal
LA English

=>

L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2004 ACS on STN
IT **149727-40-2P 162207-12-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [[[(amidinophenyl)amino]dioxoalkyl]amino]alkanoates as platelet aggregation inhibitors)
RN 149727-40-2 CAPLUS
CN Butanoic acid, 3-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-(hydroxyamino)-4-oxo-, (S)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 149727-39-9
CMF C15 H19 N5 O6

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 162207-12-7 CAPLUS
CN L-Aspartic acid, N-[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 162146-67-0
CMF C15 H18 N4 O6

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 76-05-1
CMF C2 H F3 O2



09/674,812

FILE 'HOME' ENTERED AT 15:48:23 ON 16 AUG 2004)

FILE 'REGISTRY' ENTERED AT 15:48:43 ON 16 AUG 2004
L1 STRUCTURE UPLOADED
L2 79 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:50:10 ON 16 AUG 2004
L3 4 S L2

FILE 'REGISTRY' ENTERED AT 15:55:21 ON 16 AUG 2004

FILE 'CAPLUS' ENTERED AT 15:55:21 ON 16 AUG 2004

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,Ak,Cb,Cy,Hy

G2 H,Ak

G3 H,Ak

Structure attributes must be viewed using STN Express query preparation.

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:251152 CAPLUS
DN 128:321926
TI Preparation of aspartate ester inhibitors of interleukin-1β converting enzyme
IN Albrecht, Hans P.; Allen, Hamish John; Brady, Kenneth Dale; Caprathe, Bradley William; Gilmore, John Lodge; Harter, William Glen; Hays, Sheryl Jeanne; Kostlan, Catherine Rose; Lunney, Elizabeth Ann; Para, Kimberly Suzanne; et al.
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9816502	A1	19980423	WO 1997-US18514	19971009
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9749023	A1	19980511	AU 1997-49023	19971009
	AU 738341	B2	20010913		
	EP 932598	A1	19990804	EP 1997-911715	19971009
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9712530	A	19991019	BR 1997-12530	19971009
	JP 2001506974	T2	20010529	JP 1998-518519	19971009
	NO 9901677	A	19990609	NO 1999-1677	19990409
	KR 2000049048	A	20000725	KR 1999-703117	19990410
PRAI	US 1996-28322P	P	19961011		
	WO 1997-US18514	W	19971009		

OS MARPAT 128:321926
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 4 hitstr

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
IT **206863-71-0P 206863-77-6P 206863-84-5P**
206863-88-9P 206864-70-2P 206864-71-3P
206865-45-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aspartate ester inhibitors of interleukin-1β converting enzyme)
RN 206863-71-0 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[(4-amino-2-methyl-1,4-dioxobutyl)amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206863-77-6 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[(2S)-4-amino-2-methyl-1,4-dioxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206863-84-5 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[(4-amino-1,4-dioxobutyl)amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206863-88-9 CAPLUS
CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[2-methyl-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206864-70-2 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[(2S)-4-amino-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206864-71-3 CAPLUS
CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[2-(1-methylethyl)-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206865-45-4 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[4-amino-2-(1-methylethyl)-1,4-dioxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)



IT **206864-81-5P 206864-98-4P 206864-99-5P**
206865-29-4P 206865-30-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aspartate ester inhibitors of interleukin-1β converting enzyme)

RN 206864-81-5 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[(2S)-4-amino-2-methyl-1,4-dioxobutyl]amino]-5-(1,1-dimethylethoxy)-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206864-98-4 CAPLUS
CN Pentanoic acid, 5-bromo-3-[[2-methyl-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 206864-99-5 CAPLUS
CN 1-Naphthaleneacetic acid, 5-(1,1-dimethylethoxy)-3-[[2-methyl-1,4-dioxo-4-[(2-phenylethyl)amino]butyl]amino]-2,5-dioxopentyl ester (9CI) (CA INDEX NAME)



RN 206865-29-4 CAPLUS
CN Pentanoic acid, 5-bromo-3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(phenylmethoxy)amino]butyl]amino]-4-oxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206865-30-7 CAPLUS
CN 1-Naphthaleneacetic acid, 3-[[(2S)-2-(1-methylethyl)-1,4-dioxo-4-[(phenylmethoxy)amino]butyl]amino]-2,5-dioxo-5-(phenylmethoxy)pentyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>